Opinion

Video

Novel Combination Regimens for 2L mCRC: Insights from ASCO 202

Author(s):

John Marshall, MD,Al B. Benson III, MD, FACP, FACCC, FASCO

The panel examines data from the ZL-IRIAN study and Phase II study, which provide insights into second-line treatment options for patients with metastatic colorectal cancer.

  1. Dr Cohen:ZL-IRIAN study (NCT05229003; Wang C, et al. ASCO 2024. Abstract 3570)– Irinotecan plus anlotinib ± penpulimab in 2L mCRC
  2. Dr Ciombor: Ph II study (Zhao W, et al. ASCO 2024. Abstract 3571) – fruquintinib plus investigator choice of chemotherapy in 2L mCRC

Related Videos
3 experts are featured in this series.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
Squamous cell anal carcinoma | Image Credit: © Anatomy Insider - stock.adobe.com
December 20th 2024

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
December 18th 2024

FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Michael J. Pishvaian, MD, PhD, director, Gastrointestinal, Developmental Therapeutics and Clinical Research Programs, associate professor of Oncology, Johns Hopkins Medicine
December 13th 2024

Biomarker-Guided Treatment Approaches Transform Lung and GI Cancer Management

FDA
December 4th 2024

FDA Grants Accelerated Approval to Zenocutuzumab for NRG1+ NSCLC and Pancreatic Adenocarcinoma